Amantadine: An antiviral and antiparkinsonian agent

Veterinarni Medicina

Volumn 46, Issue 9-10, 2001, Pages 244-256

  Stanicova J ^a   Miskovsky P ^b   Sutiak V ^a  

^a UNIVERSITY OF VETERINARY MEDICINE   (Slovakia)

^b P J AFÁRIK UNIVERSITY   (Slovakia)

Author keywords

Chemoprophylaxis; Chemotherapy; Influenza A; M2 protein; Parkinson's disease

Indexed keywords

EID: 0035562296     PISSN: 03758427     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Aoki F. Y., Sitar S. (1988): Clinical pharmacokinetics of amantadine hydrochloride. Clin. Pharmacokinet, 14, 35-51.
2. Bauer R., McHenry J. (1974): Comparison of amantadine, placebo, and levodopa in Parkinson's disease. Neurology, 24, 715-720.
3. Beran J. (1999): Chráni nás očkovanie proti chrípke? Forum Med., 1, 30-38.
4. Blake G.J. (1990): Amantadine for influenza A. Nursing, 90, 21.
5. Boreko E.I., Pavlova N.I., Votyakov V.I. (1996): Antiviral effects of carbocyclic compounds in different concentrations. Vopr. Virusol., 3, 129-133.
6. Carrasco L. (1995): Modification of membrane permeability by animal viruses. Adv. Virus Res., 45, 61-111.
7. Chambers T.M., Shortridge K.F., Li P.H. (1994): Rapid diagnosis of equine influenza by the Directigen FLU-A enzyme immunoassay. Vet. Rec., 135, 275-279.
8. Chambers T.M., Holland R.E., Lai A.C.K. (1995a): Equine influenza - Current veterinary perspectives, Part 1. Equine Pract., 17, 19-23.
9. Chambers T.M., Holland R.E., Lai A.C.K. (1995b): Equine influenza - Current veterinary perspectives, Part 2. Equine Pract., 17, 26-30.
10. Čiampor F. (1993): Electron microscopy and confocal scanning imaging system in the process of intracellular transport and conformational changes of virus structural proteins. In: Proceedings of Multinational Congress on Electron Microscopy, Parma. 445-449.
11. Čiampor F. (1997): Modifikácia konformácie glykoproteínov a permeability membrán iónovými kanálmi kódovanými vírusmi. XIV. Biologické dni, Praha, KP9/1.
12. Čiampor F., Bayley P.M., Nermut M.V., Hirst E.M.A., Sugrue R.J., Hay A.J. (1992a): Evidence that the amantadine-induced, M2-mediated conversion of influenza A virus hemagglutinin to the low pH conformation occurs in an acidic trans golgi compartment. Virology, 188, 14-24.
13. Čiampor F., Thompson C.A., Grambas S., Hay A.J. (1992b): Regulation the of pH by the M2 protein of influenza A viruses. Virus Res., 22, 247-258.
14. Čiampor F., Varečková E., Kostolanský F. (1998): A16. Ortomyxovírusy (Čel'ad' Ortomyxoviridae). In: Žemla J., Čiampor F., Labuda M. (eds.): Špeciálna virológia. Slovac Academic Press, Bratislava. 99-106.
15. Danielczyk W. (1995): Twenty-five years of amantadine therapy in Parkinson's disease. J. Neural. Transm., 46 (Suppl.), 399-405.
16. Daniels R.S., Downie J.C., Hay A.J., Knossow M., Skehel J.J., Wang M.L., Wiley D.C. (1985): Fusion mutants of the influenza virus haemagglutinin glycoprotein. Cell, 40, 431-439.
17. De Duve C., de Barsy T., Poole B., Trouet A., Tulkens P., van Hoof F. (1974): Lysosomotropic agents. Biochem. Pharmacol., 23, 2495-2531.
18. Dolin R., Reichman R. C., Madore P., Maynard R., Linton P., Webber-Jones J. (1982): A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. New. Engl J. Med., 10, 580-583.
19. Douglas, Jr R. G. (1990): Antimicrobial agents. In: Goodman Gilman A., Rall T.W., Nies A..S., Taylor P. (eds.): Goodman and Gilman's the Pharmacological Basis of Therapeutics. Pergamon Press, New York. Chapter 51.
20. Duff K.C., Kelly S.M., Price N.C., Bradshaw J.P. (1992): The secondary structure of influenza A M2 transmembrane domain A circular dichroism study. FEBS, 311, 256-258.
21. Duff K.C., Cudmore A.J., Bradshaw J P. (1993): The location of amantadine hydrochloride and free base within phospholipid multilayers: a neutron and X-ray diffraction study. Biochim. Biophys. Acta, 1145, 149-156.
22. Duvoisin R.C. (1991): Parkinson's Disease. Raven Press, New York. Chapter 6, 75.
23. Ewart G.D., Sutherland T., Gage P.W., Cox G.B. (1996): The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. J. Virol., 70, 7108-7115.
24. Factor S.A., Molho E.S., Brown D.L. (1998): Acute delirium after withdrawal of amantadine in Parkinson's disease. Neurology, 50, 1456-1458.
25. 2 protein. J. Biol. Chem., 274, 5474-5482.
26. Goldstein J.L., Brown M.S., Anderson R.G.W., Russell D.W., Schneier W.J. (1985): Receptor-mediated endocytosis: concepts emerging from the LDL receptor system. Ann. Rev. Cell. Biol., 1, 1-39.
27. Grelak R.P., Clark R., Stump J.M., Vernier V.G. (1970): Amantadine-dopamine interaction: possible mode of action in Parkinsonism. Sci., 169, 203-204.
28. Greulich W., Fenger E. (1995): Amantadine in Parkinson's disease: pro and contra. J. Neural. Transm., 46 (Suppl.) 415-421.
29. Hallensleben W., Zocher M., Staeheli P. (1997): Borna disease virus is not sensitive to amantadine. Arch. Virol., 142, 2043-2048.
30. Hartshorne N.J., Harruff R.C., Logan B.K. (1995): Unexpected amantadine intoxication in the death of a trauma patient. Am. J. Forencis. Med. Pathol., 16, 340-343.
31. 2 ion channel protein. Semin. Virol., 3, 21-30.
32. Hay A.J., Zambon M.C. (1984): Multiple actions of amantadine against influenza viruses. In: Becker Y. (ed.): Antiviral Drugs and Interferon: The Molecular Basis of their Activity. Martinus Nijhoff Publishing, Boston. 301-315.
33. Hay A.J., Wolstenholme A.J., Skehel J.J., Smith M.H. (1985): The molecular basis of the specific anti-influenza action of amantadine. EMBO J., 4, 3021-3024.
34. Hayden F., Hoffman H., Spyker D. (1983): Differences in side effects of amantadine hydrochloride and rimantadine hydro chloride relate to differences in pharmacokinetics. Antimicrob. Agents Chemother., 23, 458-464.
35. Huber T.J., Dietrich D.E., Emrich H.M. (1999): Possible use of amantadine in depression. Pharmacopsychiatry, 32, 47-55.
36. 2 terminus. J. Cell Biol., 106, 1489-1498.
37. Jáuregui I., Urrutia I., Gamboa P.M., Antépara I. (1997): Allergic contact dermatitis from tromantadine. Invest. Allergol. Clin. Immunol., 7, 260-261.
38. Johnson R.G., Carty S.E., Scarpa A. (1981): Accumulation of amantadine by isolated chromaffin granules. Biochem. Pharmacol., 30, 763-769.
39. König P., Chwatal K., Havelec L., Riedl F., Schubert H., Schultes H. (1996): Amantadine versus biperiden: A double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disordes. Neuropsychobiology, 33, 80-84.
40. Kornhuber J., Streifler M. (1992): Adamantanamine. In: Riederer P., Laux G.,. Pöldinger W (eds.): Neuro-psychopharmaka. Bd. 5. Springer, Wien, New York. 59.
41. Kornhuber J., Retz W., Riederer P. (1995): Slow accumulation of psychotropic substances in the human brain. Relationship to therapeutic latency of neuroleptic and antidepressant drugs? J. Neural Transrn., 46 (Suppl.), 315-323.
42. Kovacs F.A., Cross T.A. (1997): Transmembrane four-helix bundle of influenza A M2 protein channel: Structural implications from helix tilt and orientation. Biophys. J., 73, 2511-2517.
43. Kraus G.A., Zhang W., Fehr M.J, Petrich J.W., Wannemuehler Y., Carpenter S. (1996): Research at the interface between chemistry and virology: Development of a molecular flashlight. Chem. Rev., 96, 523-535.
44. + channel. J. Mol. Biol., 286, 951-962.
45. Lamb R.A., Zebedee S.L., Richardson C-D. (1985): Influenza virus M2 protein is an integral membrane protein expressed on the infected cell surface. Cell, 40, 627-633.
46. Martin J., Navas S., Fernández M., Rico M., Pardo M., Quiroga J.A., Zahm F., Carreno V. (1999): In vitro effect of amantadine and Interferon α-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients. Antivir. Res., 42, 59-70.
47. Mellman I., Fuchs R., Helenius A. (1986): Acidification of the endocytic and exocytic pathways. Ann. Rev. Biochem., 55, 663-700.
48. Monto A.S. (1994): Using antiviral agents to control outbreaks of influenza A infection. Geriatrics, 49, 30-34.
49. Nahata M.C., Brady M.T. (1986): Serum concentrations and safety of Rimantadine in paediatric patients. Eur. J. Clin. Pharmacol., 30, 719-722.
50. Nair S.K., Christianson D.W. (1991): Unexpected pH-dependent conformation of His-64, the proton shuttle of carbonic anhydride II. J. Am. Chem. Soc., 113, 9455-9458.
51. Ohkuma S., Poole B. (1981): Cytoplasmic vacuolation of mouse peritoneal macrophages and the uptake into lysosomes of weakly basic substances. J. Cell. Biol., 90, 656-664.
52. Oxford J.S. (1997): Amantadine in man and horse - can we learn from each other. Equine Vet, J., 29, 89-91.
53. Parks G.D., Lamb R.A. (1991): Topology of eukaryotic Type I membrane proteins: importance of N-terminal positively charged residues flanking the hydrophobic domain. Cell, 64, 777-787.
54. Perrin D.D., Hawkins I. (1972): Dissociation constant of the 1-aminoadamantane cation. Experientia, 28, 880.
55. Pfeiffer R.F. (1996): Amantadine-induced "Vocal" myoclonus. Movement Disord., 11, 104-106.
56. 2 protein has ion channel activity. Cell, 69, 517-528.
57. 2 proton channel of influenza A virus suggests a mechanism for its ion selectivity. Proc. Natl. Acad. Sci. USA, 94, 11301-41306.
58. Rees W.A., Harkins J.D., Woods W.E., Blouin R.A., Lu M., Fenger C., Holland R.E., Chambers T.M., Tobin T. (1997): Amantadine and equine influenza: pharmacology, pharmacokinetics and neurological effects in the horse. Equine Vet. J., 29, 104-110.
59. Richman D.D., Yazaki P., Hostetler K.Y. (1981): The intracellular distribution and antiviral activity of amantadine. Virology, 112, 81-90.
60. Ruigrok R.W.H., Hirst E.M.A., Hay A.J. (1991): The specific inhibition of influenza A virus maturation by amantadine: an electron microscopic examination. J. Gen. Virol., 72, 191-194.
61. Sabó A. (1998): Ekológia vírusu chrípky rodu A a mechanizmy vzniku nových subtypov vírusu. Slov. Vet. Čas., 23, 4-19.
62. Shimbo K., Brassard D., Lamb R., Pinto L. (1996): Ion selectivity and activation of the M2 ion channel of influenza virus. Biophys. J., 70, (3), 1335-1346.
63. Schwab R., Poskanzer D., England A., Young R. (1972): Amantadine in Parkinson's disease. JAVMA, 222, 792-795.
64. Silverman D.N., Lindskog S. (1988): The catalytic mechanism of carbonic anhydrase: Implications of a rate-limiting protolysis of water. Ace. Chem. Res., 21, 30-36.
65. Skehel J.J., Hay A.J., Armstrong J.A. (1978): On the mechanism of inhibition of influenza virus replication by amantadine hydrochloride. J. Gen. Virol., 38, 97-110.
66. Smith J.P. (1996): Treatment of chronic hepatitis C with amantadine-hydrochloride. In: Ann. Meet. of Am. Gastroenter. Assoc. and Am. Ass. for Study of Liver Dis., May 19-22.
67. Staničová J., Kovalčík L., Chinsky L., Miškovský P. (2001): Pre-resonance Raman and surface-enhanced Rarnan spectroscopy study of the complex of the antiviral and antiparkinsonian drug amantadine with histidine. Vib. Spectrosc., 25, 41-51.
68. Sugrue R.J., Hay A.J. (1991): Structural characteristics of the M2 protein of influenza A viruss: Evidence that it forms a tetrametric channel. Virology, 180, 617-624.
69. Sugrue R.J., Bahadur G., Zambon M.C., Hall-Smith M., Douglas A.R., Hay A.J. (1990): Specific structural alteration of the influenza haemagglutinin by amantadine. EMBO J., 9, 3469-3476.
70. Tamblyn S.E. (1997): Amantadine use in influenza outbreaks in long-term care facilities. Can. Med Assoc. J., 157, 1573-1574.
71. Van Laar T., Lammers G.J., Roos R.A.C., Gerritsen J.J., Meinders A.E. (1998): Antiparkinsonian drugs causing inappropriate antidiuretic hormone secretion. Movement Disord., 13, 176-178.
72. Volchow N.D., Fowler J.S., Wolf A.P., Schyler D., Shiue C., Alpert R., Dewey S.L., Logan J., Bendriem B., Christman D., Hitzmann R., Henn F. (1990): Effects of chronic cocaine abuse on post-synaptic dopamine receptors. Am. J. Psychiatr., 147, 719-724.
73. Von Heijne G. (1988): Transcending the impenetrable how proteins come to terms with membranes. Biochim. Biophys. Acta, 189, 239-242.
74. 2 protein: Characterization of the amantadine block. J. Virol., 67, 5585-5594.
75. Zebedee S.L., Lamb R.A. (1988): Influenza A virus M2 protein: Monoclonal antibody restriction of virus growth and detection of M2 in virions. J. Virol., 62, 2762-2772.
76. 2 integral membrane protein and expression at the infected-cell surface from cloned cDNA. J. Virol., 56, 502-511.
77. Zeldowicz L.R., Huberman J. (1973): Long-term therapy of Parkinson's disease with amantadine, alone and combined with levodopa. Can. Med. Assoc. J., 109, 588-593.